Edwards Lifesciences (EW) is a publicly traded Healthcare sector company. As of October 16, 2026, EW trades at $87.66 with a market cap of $49.83B and a P/E ratio of 50.16. EW moved +1.91% today. Year to date, EW is +3.25%; over the trailing twelve months it is +20.80%. Its 52-week range spans $65.94 to $96.29. Analyst consensus is strong buy with an average price target of $104.07. Rallies surfaces EW's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Rallies tracks hedge fund and 13F ownership for EW, including fund holders, share counts, and position changes when data is available.
| Metric | Value |
|---|---|
| Price | $87.66 |
| Market Cap | $49.83B |
| P/E Ratio | 50.16 |
| EPS | $1.74 |
| Dividend Yield | 0.00% |
| 52-Week High | $96.29 |
| 52-Week Low | $65.94 |
| Volume | 1.54M |
| Avg Volume | 0 |
| Revenue (TTM) | $6.51B |
| Net Income | $1.00B |
| Gross Margin | 77.84% |
17 analysts cover EW: 0 strong buy, 14 buy, 3 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $104.07.